Teladoc stock has declined significantly, from a high of $14 per share in February to $7 per share. Read why I downgrade TDOC ...

Detailed price information for Applovin Corp Cl A (APP-Q) from The Globe and Mail including charting and trades.

U.S. regulators are trying to shut down the industry for compounded weight-loss drugs, which could result in higher costs or ...

Telehealth providers, whose revenue skyrocketed amidst GLP-1 shortages, remain defiant on their compounded semaglutide ...

HIMS has experienced similar dramatic drops before. During the 2022 inflation surge, the stock fell 87%, and in 2020, it ...

The announcement adds to a string of setbacks in Pfizer’s bid to win a slice of the booming market that Wall Street projects to be worth $150 billion.

Jefferies analyst Glen Santangelo raised the firm’s price target on Hims & Hers to $25 from $21 and keeps a Hold rating on the shares. A ...

Weight loss platform Noom launched a full-page print ad in The Wall Street Journal this week, calling on policymakers to create new guidance around expensive drugs, as compounded GLP-1s are set to be ...

The telehealth company Hims & Hers is adding Zepbound and generic liraglutide to its offering of weight-loss drugs.

Through all the market madness of the past two years, there has been one truth universally acknowledged by the analysts who ...

Eli Lilly's (LLY) cease-and-desist letter is dismissed by weight loss drug compounder, OrderlyMeds. Read more here.

Eli Lilly's foray into telehealth shows the emerging importance virtual care platforms are playing in the rising popularity ...